Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

te into our Phase 3 development plan. We believe such endpoints are the only critical and relevant primary endpoints for Phase 3 trials in patients with CRPC and for ultimately achieving marketing approval."

Results from our Phase 2 clinical development program are summarized below:

    -   First Line Prostate Cancer Potential Survival Advantage - longer
        survival duration, estimated at 10.6 months, in a randomized Phase 2
        clinical trial of OGX-011 in combination with docetaxel and
        prednisone ("the OGX-011 arm") when compared to docetaxel alone ("the
        control arm") for first-line treatment of metastatic CRPC. The median
        survival was 27.5 months for the patients in the OGX-011 arm and 16.9
        months for those in the control arm. Results currently indicate that
        patients in the OGX-011 arm have a death rate of approximately 40%
        lower than patients in the control arm. Additional survival updates
        are needed before a mature median survival for the OGX-011 arm can be
        reported; however, based on the current results, OncoGenex has
        calculated that the final median survival for patients in the OGX-011
        arm cannot be lower than 22.7 months, representing at least a 5.8
        month median survival benefit. For comparison, docetaxel was approved
        for treatment of metastatic CRPC by the FDA based on a survival
        advantage of 2.4 months over mitoxantrone.

    -   Second Line Prostate Cancer Potential Survival Advantage - longer
        than expected survival durations for patients receiving OGX-011 in
        combination with either mitoxantrone or docetaxel retreatment as
        second-line chemotherapy as compared to reported survival durations
        in two published studies of CRPC patients receiving second-line
        chemotherapy. As of January 14, 2009, the median survival duration
        for the randomized 20 patien
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... MADISON, N.J., Nov. 20 At a meeting of the ... today, a dividend of fifty cents($0.50) per share on the ... 2009 to stockholders of record at the close of business,on ... Wyeth is one of the world,s largest research-driven pharmaceutical and,health ...
... SIAL ),announced today the global release of MISSION(R) ... QUALITY and iScale Oligos(TM) siRNA are,expected to allow researchers ... with the highest purity and quality siRNA required for ... be well suited to target,validation and pre-clinical siRNA testing. ...
... 20 Nephros, Inc. (Amex: NEP ), a medical device company developing ... an update on its operations and strategy. , , ... , Appointed James Scibetta ... Ernest Elgin III President and CEO , Submitted ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/24/2014)... fungus could now be treated in three days, rather than ... , Cryptococcus a form of yeast - ... research. They are found in many parts of the ... affect people with weakened immune systems. This infection kills up ... has tested the effects of the most commonly used drug ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
(Date:4/24/2014)... of clear liquid can bend light, acting as a ... developed a new process to create inexpensive high quality ... , Because they,re so inexpensive, the lenses can ... to detect diseases in the field, scientific research in ... in classrooms. , "What I,m really excited about ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Amazon rainforest survey could improve carbon offset schemes 2Bake your own droplet lens 2Bake your own droplet lens 3
... While researching methods to increase the already well-recognized ... Illinois also found a way to prolong the vegetable,s ... study, the method is a natural and inexpensive way ... and won,t spoil so quickly on your refrigerator shelf. ...
... disease is the most common form of birth defect, ... the National Institutes of Health. Researchers from the University ... treat laboratory mice with one form of congenital heart ... caused by abnormally thick muscle. By suppressing a faulty ...
... vegetables are associated with higher Body Mass Index (BMI) ... to American University researchers in the journal Pediatric ... between the prices of fruit and vegetables and higher ... and assistant professor of public administration and policy at ...
Cached Biology News:Better broccoli, enhanced anti-cancer benefits with longer shelf life 2Better broccoli, enhanced anti-cancer benefits with longer shelf life 3Compound improves cardiac function in mice with genetic heart defect, MU study finds 2High cost of fruits, vegetables linked to higher body fat in young children 2
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Probes intensely fluorescent and highly photostable ... use in a variety of applications ... strong signal. Unfortunately, protein- and other ... may cause them to bind to ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: